Key result
Diosmetin reduces myocardial infarct area by an absolute ~42% in rat models of infarction.
Why the study?
Flavonoids show efficacy in ischemic heart disease by alleviating oxidative stress and beta-1 adrenergic activation, but the underlying mechanistic link remains unclear.
Does pretreatment and co-treatment with the antioxidant flavonoid diosmetin attenuate myocardial infarction size, ECG abnormalities, and cardiac biomarker elevation in rats with isoproterenol-induced myocardial infarction?
Does pretreatment and co-treatment with the antioxidant flavonoid diosmetin attenuate myocardial infarction size, ECG abnormalities, and cardiac biomarker elevation in rats with isoproterenol-induced myocardial infarction?
In a rat model of beta 1-adrenergic receptor-induced myocardial infarction, pretreatment with the flavonoid diosmetin significantly reduced infarct size, normalized ECG abnormalities, and lowered serum cardiac injury biomarkers.
Answers are grounded in this paper and cite their sources.
Diosmetin attenuates injury in this rat model; leaves open translation to human myocardial infarction.
Myocardial infarction (MI) is a common and life-threatening manifestation of ischemic heart diseases (IHD). The most important risk factor for MI is hypertension. Natural products from medicinal plants have gained considerable attention globally due to their preventive and therapeutic effects. Flavonoids have been found to be efficacious in ischemic heart diseases (IHD) by alleviating oxidative stress and beta-1 adrenergic activation, but the mechanistic link is not clear. We hypothesized that antioxidant flavonoid diosmetin is cardioprotective in a rat model of MI induced by beta 1-adrenergic receptor activation. To test this hypothesis, we evaluated the cardioprotective potential of diosmetin on isoproterenol-induced MI in rats by performing lead II electrocardiography (ECG), cardiac biomarkers including troponin I (cTnI) and creatinine phosphokinase (CPK), CK-myocardial band, (CK-MB), lactate dehydrogenase (LDH), alanine aminotransferase (ALT), and aspartate aminotranferase (AST) by using biolyzer 100, as well as histopathological analysis. We found that diosmetin (1 and 3 mg/kg) attenuated isoproterenol-induced elevation in the T-wave and deep Q-wave on the ECG, as well as heart-to-body weight ratio and infarction size. In addition, pretreatment with diosmetin attenuated the isoproterenol-induced increase in serum troponin I. These results demonstrate that flavonoid diosmetin may provide therapeutic benefit in myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2023) studied Isoproterenol-induced myocardial infarction in rats (n=30). Diosmetin vs. Isoproterenol alone (80 mg/kg subcutaneously), vehicle control (1% DMSO), and atenolol (1 mg/kg) was evaluated on Myocardial infarct area (%) (p=<0.05). Diosmetin reduced myocardial infarct area to 13% compared to 55% in isoproterenol-treated rats and decreased serum cTnI levels by 55%.
Synapse has enriched 10 related papers. Consider them for comparative context: